Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-26

Reporting Person: Alexandria Venture Investments, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-26	Common stock	C	166423	—	Acquired	166423	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-26	Series B convertible preferred stock	$	C	1581026	Disposed		Common stock (166423.0)	Direct

Footnotes

F1: Each share of preferred stock automatically converted into the Issuer's common stock at a ratio of 9.5 shares of preferred stock to 1 share of common stock upon closing of the Issuer's initial public offering on October 22, 2021, for no additional consideration. The shares had no expiration date.

F2: Not applicable.